ICER publishes evidence report on gene therapy for beta thalassaemia


2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia.

The ICER today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of betibeglogene autotemcel or “beti-cel” (Zynteglo/LentiGlobin, bluebird bio) for the treatment of beta thalassaemia.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder